Imaging Software expedites clinical trial process.
Share:
Press Release Summary:
Providing FDA required 21 CFR Part 11 compliant tools for managing international imaging sites, VirtualScopics v2.0 includes image analysis automation system, traceability, tools for data management, and real-time detailed reports. Enabling users to conduct later stage clinical trials, it gives access to critical information earlier in process which helps in drug development.
Original Press Release:
VirtualScopics Releases Next Generation Software Platform for Imaging in Clinical Trials
ROCHESTER, N.Y., May 21 -- VirtualScopics, Inc. (NASDAQ:VSCP), a leading developer of image-based biomarker solutions, announced today that it released its next generation 2.0 software platform for the use of imaging in clinical trials. This industry-leading platform draws upon seven years of experience in imaging to deliver operational efficiencies and enhanced reporting in order to expedite customers' clinical trial process.
The new platform provides FDA required 21 CFR Part 11 compliant tools for managing international imaging sites. These latest capabilities give the VirtualScopics a scalable global reach that is essential to conducting later stage clinical trials. The software platform includes a new image analysis automation system, improved traceability, enhanced tools for data management, in addition to real-time detailed reports for VirtualScopics' customers.
"We are excited about the release of the 2.0 platform as it not only makes us more efficient in later stage clinical trials but also incorporates many features that our customers have requested relative to reporting and data mining. These enhancements provide our customers access to critical information earlier in the process, to further accelerate drug development," said Jeff Markin, president and chief executive officer of VirtualScopics, Inc. "This software release provides a solid platform for additional planned releases that will enhance our ability to provide real-time information to our customers on a global basis."
About VirtualScopics, Inc.
VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics' industry- leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit www.virtualscopics.com.
Source: VirtualScopics, Inc.
Web site: www.virtualscopics.com/
